Replies to post #157225 on Biotech Values

[pollyvonwog]

To clarify, MNTA never had a chance to defend it's patents. The CAFC ruling had to do with safe harbour and nothing to do with the actual patents.

[DewDiligence]

AMRN—When I looked into Lovaza patent portfolio on the FDA OB site, Lovaza has only 3 patents listed whereas Vascepa has 8 currently listed and counting related to the Anchor trial.

What matters is not the quantity of patents in the Orange Book, but rather the quality. AMRN’s patents will (IMO) be challenged on the basis of obviousness.